Statement re Clinical Trial

RNS Number:8094I
Amarin Corporation Plc
29 November 2007


         AMARIN COMMENCES FIRST CLINICAL TRIAL IN CARDIOVASCULAR PROGRAM


    Initiates Phase I Clinical Trial to Evaluate Ultra-Pure Ethyl EPA-Niacin

                   for Treatment of Niacin- Induced Flushing



LONDON, United Kingdom, November 29, 2007 - Amarin Corporation plc (NASDAQ:
AMRN) today announced that it has commenced a phase I clinical safety and
efficacy trial in volunteers. The trial will evaluate the co-administration of
ultra-pure ethyl EPA and niacin on niacin induced flushing. Flushing is a common
side effect of niacin treatment which significantly limits patient compliance.


Niacin is a treatment used to increase High Density Lipoprotein (HDL) and
modestly decrease triglyceride levels in dyslipidemia or cholesterol management.
Ultra-pure ethyl EPA has been prescribed in Japan for over 15 years for the
treatment of triglyceride lowering. Ultra-pure ethyl EPA is known to have
several additional beneficial effects in cardiovascular disease.


Rick Stewart, Chief Executive Officer commented, "The initiation of this study
is significant because it marks the commencement of Amarin's cardiovascular
development program and potentially addresses a major medical need. Niacin is a
valuable addition to the treatment of dyslipidemia but its principal drawback is
flushing."


Mr. Stewart continued, "Amarin's cardiovascular program capitalizes on the known
therapeutic benefits of ultra-pure EPA in cardiovascular disease and is a
logical extension from Amarin's existing therapeutic base for ultra-pure EPA and
its derivatives. By using ultra-pure EPA and niacin together, both HDL and
triglycerides can be managed. We believe this combination can be a useful
therapeutic proposition. We are fortunate to have the know-how, the intellectual
property, the resources and the ability to draw on an extensive knowledge
network in cardiovascular disease and look forward to continuing to report our
progress with these exciting new programs."


Amarin intends to develop its dyslipidemia and metabolic syndrome cardiovascular
development pipeline and will seek partners to further develop and commercialize
if efficacy is proven.


Amarin's Cardiovascular Development Program

Amarin's cardiovascular development strategy is to capitalize on the known
therapeutic benefits of unsaturated fatty acids in cardiovascular disease.
Amarin plans to utilize its extensive know-how, intellectual property and
experience in lipid science to develop a series of products targeting the
vascular system.

Amarin intends to commence a series of clinical trials with AMR 101 (97% pure
EPA) for the treatment of metabolic syndrome and dyslipidemia. AMR 101 is
believed to impact on a number of biological factors all of which contribute to
vascular remodelling where endothelial dysfunction exists. Endothelial
dysfunction is a condition that underlies vascular disease. Patients with
cardiovascular disease often suffer from multiple conditions. The most prevalent
type is hypertension, or high blood pressure, with 85% of U.S. Coronary Heart
Disease (CHD) patients suffering from this condition. Over 50% of U.S. CHD
patients have concomitant dyslipidemia, including elevated blood cholesterol
levels.

It is estimated that total U.S. pharmaceutical sales in the cardiovascular
segment in 2006 were approximately $43.7 billion. The dyslipidemia market,
excluding statins, was estimated at approximately $2.2 billion in 2006,
representing a compound annual growth rate of 31% since 2002. The major driver
of this growth is believed to be an overall broadening of dyslipidemia treatment
beyond reduction in Low Density Lipoprotein (LDL) cholesterol.

About Dyslipidemia


Dislipidemia can be manifested by elevation of total cholesterol, the "bad"
low-density lipoprotein (LDL) cholesterol and triglyceride concentrations, and a
decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration
in the blood.


About metabolic syndrome


Metabolic syndrome is characterized by a group of metabolic risk factors in one
person. They include:

   *Obesity
   *Dyslipidemia
   *Elevated blood pressure
   *Insulin resistance or glucose intolerance.

People with metabolic syndrome are at increased risk of coronary heart disease
and other vascular (e.g., stroke and peripheral vascular disease) and type 2
diabetes. Metabolic syndrome has become increasingly common in the United
States. It is estimated that over 50 million Americans have metabolic syndrome.

About Amarin

Amarin is committed to improving the lives of patients suffering from central
nervous system and cardiovascular diseases. Our goal is to be a leader in the
research, development and commercialization of novel drugs that address unmet
patient needs.

Amarin's CNS development pipeline includes Miraxion for Huntington's disease,
two programs in Parkinson's disease, one in epilepsy and one in memory and
cognition. Amarin is initiating a series of cardiovascular preclinical and
clinical programs to capitalize on the known therapeutic benefits of essential
fatty acids in cardiovascular disease. Amarin also has a proprietary lipid-based
technology platform for the targeted transport of molecules through the liver
and/or to the brain that can be leveraged in a wide range of disease
applications for its own product pipeline or with potential partners.

Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and
secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"),
respectively.

For press releases and other corporate information, visit the Amarin website at
http://www.amarincorp.com. Information on our website does not form part of this
press release.


Contacts:
Amarin +44 (0) 207 907 2442
Rick Stewart, Chief Executive Officer
Alan Cooke, President and Chief Financial Officer
investor.relations@amarincorp.com

Investors:
Lippert/Heilshorn & Associates, Inc. +1 212 838 3777
Anne Marie Fields
Bruce Voss +1 310 691 7100

Media:
Powerscourt +44 (0) 207 250 1446
Rory Godson
Sarah Daly

Disclosure Notice


The information contained in this document is as of November 29, 2007. Amarin
assumes no obligation to update any forward-looking statements contained in this
document as a result of new information or future events or developments. This
document contains forward-looking statements about Amarin's financial condition,
results of operations, business prospects and products in research that involve
substantial risks and uncertainties. You can identify these statements by the
fact that they use words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe" and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance or events. Among the factors that could cause actual
results to differ materially from those described or projected herein are the
following: risks relating to the Company's ability to maintain its Nasdaq
listing (including the risk that the Company may not be able to achieve
compliance with the Nasdaq minimum bid price and/or other continued listing
criteria within the required timeframe or at all and the risk that the Company
may not be able to successfully appeal a Nasdaq delisting determination); the
success of Amarin's research and development activities, including its planned
clinical trials in cardiovascular disease; decisions by regulatory authorities
regarding whether and when to approve Amarin's drug applications, as well as
their decisions regarding labeling and other matters that could affect the
commercial potential of Amarin's products; the speed with which regulatory
authorizations, pricing approvals and product launches may be achieved; the
success with which developed products may be commercialized; competitive
developments affecting Amarin's products under development; the effect of
possible domestic and foreign legislation or regulatory action affecting, among
other things, pharmaceutical pricing and reimbursement, including under Medicaid
and Medicare in the United States, and involuntary approval of prescription
medicines for over-the-counter use; Amarin's ability to protect its patents and
other intellectual property; claims and concerns that may arise regarding the
safety or efficacy of Amarin's product candidates; governmental laws and
regulations affecting Amarin's operations, including those affecting taxation;
Amarin's ability to maintain sufficient cash and other liquid resources to meet
its operating requirements; general changes in International and US generally
accepted accounting principles; growth in costs and expenses; and the impact of
acquisitions, divestitures and other unusual items. A further list and
description of these risks, uncertainties and other matters can be found in
Amarin's Form 20-F for the fiscal year ended December 31, 2006, filed with the
SEC on March 5 2007, Amarin's statutory annual report for the year ended 31
December, 2006 furnished on a Form 6-K to the SEC on May 9, 2007 and in its
Reports of Foreign Issuer on Form 6-K furnished to the SEC.

Ends



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
STREKLFLDFBFFBX
Amarin (LSE:AMRN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024